Retrospective study links IVIG plus azithromycin to higher response rate in pediatric Mycoplasma pneumoniae pneumonia

A single-center retrospective cohort study evaluated 140 children with Mycoplasma pneumoniae pneumonia. The intervention group received intravenous immunoglobulin (IVIG) plus azithromycin sequential therapy, while the control group received azithromycin sequential therapy alone. The primary outcome was the total effective rate, which was higher in the IVIG group (97.14%) compared to the control group (84.29%), a difference that was statistically significant (p < 0.05). Secondary outcomes included time to symptom resolution, inflammatory cytokine levels, immunoglobulin levels, and pulmonary function, but specific numerical results for these were not reported in the provided data.

Regarding safety, the study reported that the combination therapy was administered without increasing adverse events. However, specific rates of adverse events, serious adverse events, or treatment discontinuations were not reported.

Key limitations of this evidence include its retrospective design, which prevents establishing causality, and the potential for residual confounding. Disease severity was also not formally stratified between groups, which could influence the observed outcomes. The study was conducted at a single center, and follow-up duration was not reported.

For clinical practice, this study suggests a potential association between adjunctive IVIG and improved clinical response in this pediatric population. However, the retrospective nature and lack of detailed safety reporting mean these findings should be considered preliminary. They highlight an area for prospective, controlled investigation rather than providing definitive guidance for routine care.